Clinical research remains concentrated in only a few places, limiting access to new treatments. #ATMI24 shows that only 43% of #ClinicalTrials took place in any #LMICs, despite these countries being home to nearly 80% of the global population. Read more➡️ tinyurl.com/mry2kb8p #Access2Meds
For the first episode of The #HealthEquity podcast, our CEO, @jayiyer.bsky.social, sat down with Dr Joseph Saba, CEO of Axios International, to discuss #ATMI24 & how #pharma is addressing access challenges. What’s working, what’s not & what comes next? Listen to the podcast series➡️ bit.ly/45gcjjL
📣 Register for our upcoming #webinar on bridging gaps in access to #healthcare, co-hosted by @medicinespatentpool.org & the Ecumenical Pharmaceutical Network. Join us on 10 April to discuss the #ATMI24 findings & the role of #pharma companies in driving change. Learn more ➡️ bit.ly/3DZQDNX
The first episode of The Access Podcast is here! 🎙️
Our CEO, @jayiyer.bsky.social, speaks with Dr Joseph Saba of Axios International about #ATMI24 & how #pharma is addressing access challenges. What’s working, what’s not & what comes next?
Listen now➡️ accesstomedicinefoundation.org/featured-ins...
Our team is at #EPAConf in Amsterdam today, engaging with key stakeholders on #healthcare access & #pharma accountability. Our CEO, @jayiyer.bsky.social, will deliver a keynote speech sharing insights on global #HealthEquity from the 2024 #AccesstoMedicine Index #ATMI24. Learn more➡️ bit.ly/4isqENQ
In an op-ed for @weforum.org, the Foundation's CEO, @jayiyer.bsky.social, argues that equitable #AccesstoMedicine isn't just a moral imperative but a strategic opportunity for sustainable returns & discusses the key insights from #ATMI24. Read the op-ed➡️ bit.ly/40WPLlC #HealthEquity #ESG
#NCDs are the number one cause of death & disability worldwide. The 2024 #AccesstoMedicine Index #ATMI24 finds that voluntary licensing continues to be a severely underutilised mechanism in NCDs, with 26/27 licences analysed covering communicable diseases. Learn more➡ bit.ly/3NUREIk
#ATMI24 spotlights eight Best Practices that exemplify how #pharma companies are driving progress toward equitable #AccesstoMedicine, each highlighting proven actions that not only address current challenges but also elevate industry standards. Learn more➡ bit.ly/4goFOCf #HealthEquity #GlobalHealth
Has the #pharma industry advanced in achieving global #HealthEquity? The 2024 #AccesstoMedicine Index #ATMI24 finds that while some modest progress has been made, the potential for improving access is still far from realised. Read the key findings➡ bit.ly/3ra4URP
#GlobalHealth #EquitableAccess
2024 Access to Medicine Index overall ranking
How do the companies compare in #ATMI24? Novartis takes the top spot, followed closely by GSK. While both companies stand out as leaders, & other companies have demonstrated strong performances within specific areas, the overall industry progress is stalling. Learn more➡ bit.ly/3ra3F57
Last year, we launched #ATMI24, showcasing an overall stagnation in #pharma companies’ efforts to improve access to essential healthcare products across #LMICs. While some modest progress has been made, the potential for improving access is still far from realised. Read more➡️ bit.ly/3NUREIk
